Wright Kim, Dodd Alyson L, Warren Fiona C, Medina-Lara Antonieta, Dunn Barnaby, Harvey Julie, Javaid Mahmood, Jones Steven H, Owens Christabel, Taylor Rod S, Duncan Deborah, Newbold Alexandra, Norman Shelley, Warner Faith, Lynch Thomas R
Washington Singer Labs., University of Exeter Department of Psychology, Perry Road, Exeter, EX4 4QG, UK.
Int J Bipolar Disord. 2021 Jul 1;9(1):20. doi: 10.1186/s40345-021-00226-4.
A subgroup of those with bipolar spectrum disorders experience ongoing mood fluctuations outside of full episodes. We conducted a randomised, controlled feasibility study of a Dialectical Behavioural Therapy-informed approach for bipolar mood fluctuations (Therapy for Inter-episode mood Variability in Bipolar [ThrIVe-B]). Our study aimed to examine the feasibility and acceptability of a future definitive trial evaluating the clinical and cost effectiveness of the ThrIVe-B programme. Participants were required to meet diagnostic criteria for a bipolar spectrum disorder and report frequent mood swings outside of acute episodes. They were randomised to treatment as usual (control arm) or the ThrIVe-B intervention plus treatment as usual (intervention arm). Follow-up points were at 3, 6, 9 and 15 months after baseline, with 9 months as the primary end point. To evaluate feasibility and acceptability we examined recruitment and retention rates, completion rates for study measures, adverse events and feedback from participants on their experience of study participation and therapy.
Of the target 48 participants, 43 were recruited (22 in the intervention arm; 21 in the control arm), with a recruitment rate of 3.9 participants per month. At 9 months 74% of participants engaged in research follow-up assessment, exceeding the pre-specified criterion of 60%. There were no serious concerns about the safety of the research procedures or the intervention. On one of the four candidate primary outcome measures, the 95% CI for the between-group mean difference score excluded the null effect and included the minimal clinically important difference, favouring the intervention arm, whilst on no measure was there evidence of deterioration in the intervention arm relative to the control arm. Attendance of the intervention (50% attending at least half of the mandatory sessions) was below the pre-specified continuation criterion of 60%, and qualitative feedback from participants indicated areas that may have hampered or facilitated engagement.
It is broadly feasible to conduct a trial of this design within the population of people with frequent bipolar mood swings. Changes should be made to the therapy to increase uptake, such as simplifying content and considering individual rather than group delivery. Trial registration ISRCTN: ISRCTN54234300. Registered 14th July 2017, http://www.isrctn.com/ISRCTN54234300.
双相情感障碍谱系障碍患者的一个亚组在完整发作之外经历持续的情绪波动。我们对一种基于辩证行为疗法的双相情感波动治疗方法(双相情感障碍发作间期情绪变异性治疗[ThrIVe-B])进行了一项随机对照可行性研究。我们的研究旨在检验未来一项评估ThrIVe-B方案临床和成本效益的确定性试验的可行性和可接受性。参与者需符合双相情感障碍谱系障碍的诊断标准,并报告在急性发作之外频繁的情绪波动。他们被随机分配至常规治疗组(对照组)或ThrIVe-B干预加常规治疗组(干预组)。随访时间点为基线后的3、6、9和15个月,以9个月作为主要终点。为评估可行性和可接受性,我们考察了招募和留存率、研究测量的完成率、不良事件以及参与者对其参与研究和治疗体验的反馈。
在目标招募的48名参与者中,招募到43名(干预组22名;对照组21名),每月招募率为3.9名参与者。在9个月时,74%的参与者参与了研究随访评估,超过了预先设定的60%的标准。对研究程序或干预的安全性没有严重担忧。在四项候选主要结局指标中的一项上,组间平均差异得分的95%置信区间排除了无效效应,并包含了最小临床重要差异,有利于干预组,而在任何指标上均没有证据表明干预组相对于对照组出现恶化。干预的参与率(50%的参与者至少参加了一半的必修课程)低于预先设定的60%的继续标准,参与者的定性反馈指出了可能阻碍或促进参与的方面。
在频繁出现双相情感波动的人群中进行这种设计的试验总体上是可行的。应改变治疗方法以提高参与度,例如简化内容并考虑采用个体而非团体治疗方式。试验注册号:ISRCTN: ISRCTN54234300。于2017年7月14日注册,http://www.isrctn.com/ISRCTN54234300。